Allyson J. Ocean, Oncology Innovator, Board Director, Global Patient Advocate shared a post by Novocure on LinkedIn:
“The approval of Tumor Treating Fields for Pancreatic cancer is truly Electrifying news.
Developed by Novocure , this therapy uses low-intensity alternating electric fields to disrupt cancer cell division, interfering with mitosis while largely sparing normal tissue. It introduces a completely different mechanism into a disease space that has long needed new energy.
For patients facing one of the most lethal cancers, this approval sends a Powerful Current of Hope. It expands treatment options beyond traditional drugs and proves that innovation in pancreatic cancer is not static, it is charged dynamic, and moving forward.
I am deeply honored to serve on the Board of Novocure at this pivotal moment. To be connected to a mission that is helping power a new era in pancreatic cancer care feels both humbling and energizing.
Sometimes progress comes in waves. This time, it comes in electric ones.”
Quoting Novocure‘s post:
“The U.S. Food and Drug Administration (FDA) has approved Novocure’s treatment for adult patients with locally advanced pancreatic cancer concurrently with gemcitabine and nab-paclitaxel.”
Other articles featuring Pancreatic Cancer on OncoDaily.